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The regulatory circuit controlling cellular protein phosphatase-1 (PP1), an abundant group of Ser/Thr 
phosphatases, involves phosphorylation of PP1-specific inhibitor proteins. Malfunctions of these inhibitory 
proteins have been linked to a variety of diseases, including cardiovascular disease and cancer. Upon 
phosphorylation at Thr38, the 17-kDa PP1 inhibitor protein, CPI-17, selectively inhibits a specific form of PP1, 
myosin light chain phosphatase (MLCP), which transduces multiple kinase signals into the phosphorylation of 
myosin-II and other proteins.  Here, the mechanisms underlying PP1 inhibition, and the kinase/PP1 crosstalk 
mediated by CPI-17 and its related proteins, PHI, KEPI, and GBPI, are discussed. 
 
Introduction   
The reciprocal activities of protein kinases and phosphatases determine protein phosphorylation levels 
in cells. PP11 dephosphorylates phospho-Ser/Thr residues of proteins, to regulate multiple signal pathways at 
various cellular loci (1-3).  Cellular PP1 is associated with PP1 regulatory protein/subunits at their PP1-binding 
site, known as the RVXF motif.  The binding of PP1 regulatory proteins thus confers substrate specificity and 
localization on cellular PP1. Nearly 100 polypeptides have been identified as PP1 regulatory proteins and these 
account for the wide spectrum of PP1 function (1-3).  In addition, eukaryotic cells express several PP1 inhibitor 
proteins that play important roles in regulating cellular PP1.  The first generation of PP1 inhibitor proteins 
involves inhibitor-1, inhibitor-2, DARPP32 and NIPP-1, which potently inhibit the free catalytic subunit of PP1, 
but these inhibitor proteins were much less potent toward purified PP1 holoenzymes, MLCP and the glycogen-
bound PP1. Therefore, cellular PP1 holoenzymes were thought to undergo subunit dissociation prior to the 
inhibition of PP1 by the inhibitor proteins (1,2). However, the number of PP1 holoenzymes that do undergo 
subunit dissociation in cells remains unclear. 
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MLCP is a trimeric PP1 holoenzyme, consisting of a PP1∂ isoform and a regulatory complex of MYPT1 
(a.k.a. MBS, M110) regulatory and M21 accessory subunits that govern myosin-II phosphorylation (4).  MYPT1 
and PP1 bind through the MYPT1 KVKF segment, as well as its 8-repeat ankyrin motif at the N-terminal 
domain (5). Binding of the N-terminal 300-residue domain of MYPT1 is sufficient to allosterically regulate PP1 
activity.  The MYPT1 C-terminal domain directly binds to substrates, including myosin and 
ezrin/radixin/moesin (4). MLCP activity is tightly regulated in response to various signals.  For example, in 
smooth muscle, activation of the G-protein coupled receptor inhibits MLCP resulting in increased Ca2+ 
sensitivity of myosin phosphorylation and contraction, whereas cyclic nucleotide signals can activate MLCP to 
induce smooth muscle relaxation (6).  MLCP inhibition occurs upon MYPT1 phosphorylation at Thr696 and 
Thr853 (4).  On the other hand, cGMP-K can activate MLCP (7).  These regulatory signals are MYPT1 isoform-
dependent (8), suggesting an important role for MYPT1 in MLCP regulation.  In addition, we identified the 
MLCP inhibitor protein, named CPI-17, which transduces G-protein signals into MLCP inhibition (9,10).  Based 
on sequence similarity, three CPI-17 homologues, PHI, KEPI and GBPI, in the human genome were 
characterized as PP1 inhibitors (11-13).  Each CPI-17 family member carries a PP1 holoenzyme inhibitory 
(PHIN) domain, where the sequences are >41 % identical to CPI-17 (Fig. 1A).  Indeed, all CPI-17 family 
members potently inhibit MLCP activity, which suggests new avenues for PP1 holoenzyme inhibition.  This 
Minireview will focus on CPI-17 and its homologues, whose amino acid sequences differ significantly from 
other PP1 inhibitor proteins, highlight critical findings from CPI-17 studies, and discuss the role of other CPI-17 
family members in regulating PP1 activity.  
 
Structure and function of CPI-17  
  Amino acid sequence of CPI-17: The CPI-17 gene (PPP1R14A, chromosome 19) encodes a 147-residue 
polypeptide where >85 % of the amino acids are identical within mammals (10) (Fig. 1A). A splice variant of 
CPI-17 (CPI-17β) lacking exon 2 exists in human smooth muscle cells, although whether this form is 
physiologically relevant is not known (see subsequent section) (14).  Zebrafish express a similar gene, although 
to which CPI-17 family member this gene product is functionally related is unclear.  No homologous genes have 
been detected in fruit fly, nematode, and yeast genes, suggesting that the CPI-17 family emerged at a late stage 
in evolution.  Phosphorylation of CPI-17 at Thr38 is necessary and sufficient to convert the protein into a potent 
MLCP inhibitor (9,10). No homology is detected between the CPI-17 family and other classes of PP1 inhibitors, 
such as inhibitor-1 and inhibitor-2, even though phosphorylation is also involved in the function of most other 
PP1 inhibitor proteins.  The CPI-17 structure has three domains: N- and C-terminal tails and the central 86-
residue PHIN domain between residues 35 to 120 (Fig. 1A) (15). The sequence surrounding the inhibitory 
phosphorylation site characterizes the CPI-17 family, and is pseudo palindromic, (basic)-(hydrophobic)-Thr-
(hydrophobic)-(basic) (16).  Tyr41, Asp42 and Arg43 of CPI-17 are necessary for the inhibitory activity, and 
also conserved among CPI-17 family members (15).  Substitution of Ala at CPI-17 Tyr41 accelerates phospho-
Thr38 dephosphorylation, the significance of which will be discussed (15).  In contrast to the PHIN domain, 
both the N- and C-terminal tail domains are unique for each CPI-17 family member. The other CPI-17 family 
members do possess the putative PP1 binding RVXF motif, which is located at the N-terminal tails of PHI, 
KEPI and GBPI (Fig. 1A, green box) (11-13).  
 
  3D structure of CPI-17:  Solution NMR studies revealed the 3D structure of unphosphorylated and phospho-
CPI-17 PHIN domains (16).  The structure of the CPI-17 PHIN domain consists of a loop structure 
encompassing the phosphorylation site Thr38 (P-loop), followed by a four-helix bundle that stabilizes the P-loop 
structure (shown in Fig. 1A, bottom) (16).  Fig. 2 shows the 3D structural models of unphosphorylated and 
phospho-CPI-17.  In the unphosphorylated form, two paired A/D and B/C helices form a V shape structure with 
the P-loop situated between the paired helices (Fig. 2, left). Upon Thr38 phosphorylation, the P-loop becomes 
more solvent exposed, and in doing so, generates torque in the A-helix.  This twisting of the A-helix rolls the A-
B loop up to align the B/C helices in parallel with the A/D helices (Fig. 2, center).  The newly aligned four 
helices are then stabilized through a hydrophobic core that is created by the rearrangement. The P-loop of 
phospho-CPI-17 is now displayed on the molecular surface, tethered by Tyr41.  Presumably, the anchoring 
function of Tyr41 is necessary to prevent dephosphorylation of the MLCP active site. The phosphate group at 
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Thr38 cannot be replaced with Asp, which causes P-loop dislocation with a minimal increase in inhibitory 
potency, or with Glu, which distorts the overall structure.  Furthermore, substitution of a cysteine-derived 
sulphonic acid side chain at Thr38 cannot mimic phosphorylation.   Thus, the phosphate group seems to play a 
specific role for CPI-17’s potent inhibitory activity beyond only being a trigger of conformational change. The 
splice variant CPI-17β retains the P-loop and the A/D-helix pair, although whether this isoform can inhibit PP1 
or functions as a dominant negative form in the cell is not known. Based on the sequence similarity in the PHIN 
domain, the structural topology and as such the function is likely conserved for CPI-17 family members. 
 
  Selective inhibition of MLCP by phospho-CPI-17:  Phospho-CPI-17 selectively inhibits the MLCP complex 
with an IC50 value of around 1 nM (17,18).  How then can CPI-17 recognize only the PP1 associated with 
MYPT1 among nearly one hundred other PP1 holoenzymes that exist in cells?  Fig. 2 illustrates our current 
model for the selective inhibition of MLCP by phospho-CPI-17. PP1 associated with MYPT1 is unable to 
hydrolyze the phospho-Thr38 of CPI-17, so that phospho-CPI-17 forms a stable complex with MLCP (Fig. 2, 
left).  On the other hand, other PP1 holoenzymes are able to dephosphorylate phospho-CPI-17 and neutralize its 
inhibitory potency.  Simply put, the PP1 regulatory subunit determines whether phospho-CPI-17 is an inhibitor 
or substrate of PP1. A kinetic analysis suggests a mixed inhibition of MLCP is induced by phospho-CPI-17, 
with Ki and Ki’ values of 1.9 nM and 5.1 nM, respectively (17).  Indeed, computer modeling predicts a direct 
contact between phospho-CPI-17 and MYPT1 (Fig. 2, right), which may account for CPI-17’s specific 
inhibition of MLCP (16). Fig. 1B illustrates the electrostatic surface potential of phospho-CPI-17 and the 
predicted maps for other CPI-17 homologues calculated from sequence alignments.  The docking surface of 
CPI-17 (Fig. 1B left) consists of positively charged residues surrounding an acidic island of phospho-Thr38 
(cyan arrow).  The positively charged regions around phospho-Thr38 seem to complement the acidic cluster 
formed by PP1 and the MYPT1 ankyrin repeat domain (5). The pattern of surface potential varies within the 
CPI-17 family, whereas the negative charge dominates in models of PHI-1 and KEPI structures, and the positive 
charge is clustered at the edge of GBPI (Fig. 1B). The differences in the structure of the docking surface suggest 
that each CPI-17 homologue selectively controls a specific subset of target PP1 holoenzymes and cellular 
events. 
 
Role of CPI-17 in cell signaling 
  Kinases and phosphatases regulating CPI-17:  Multiple kinases and phosphatases are involved in regulating 
CPI-17 phosphorylation. In smooth muscle, CPI-17 phosphorylation occurs in response to agonist stimulation 
through activation of PKC, ROCK and ILK (19,20). Indeed, PKC α and δ are the dominant kinases for CPI-17 
in pig aorta smooth muscle extracts (21). Also, CPI-17 binds to the regulatory domain of PKC isoforms, 
including α, ε, λ, ζ, and µ (22). Zipper-interacting kinase and p21-activated kinase are also known to directly 
phosphorylate isolated CPI-17 at Thr38 (23,24). Thus, CPI-17 is expected to function as a hub of multiple 
kinase signals that control MLCP activity. For example, α1-adrenergic receptor stimulation produces bi-phasic 
phosphorylation of CPI-17 through the sequential activation of PKC and ROCK in smooth muscle (25).  The G-
protein coupled receptor-induced rapid activation of Ca2+-dependent PKC elicits acute CPI-17 phosphorylation, 
causing MLCP inhibition, which amplifies the Ca2+-calmodulin-dependent myosin light chain kinase signal.  
Following Ca2+ withdrawal, the delayed and sustained activation of ROCK maintains CPI-17 and MYPT1 
phosphorylation, causing tonic smooth muscle contraction (25). Thus, the combination of kinase signals confers 
the profile of smooth muscle force generation through CPI-17 phosphorylation. CPI-17 phosphorylation 
reversibly declines in response to elevated cAMP/cGMP levels (26), which attenuate PKC and ROCK signals 
(27).  In addition, treatment with a cGMP analog possibly activates unidentified phosphatase(s) that can 
dephosphorylate CPI-17 (28).  In our model, CPI-17 is dephosphorylated by such “other” PP1 complexes (Fig. 
2) (18).  In addition, purified protein phosphatase 2A and 2C are capable of dephosphorylating CPI-17 (29), 
suggesting the possible involvement of multiple phosphatases in regulating CPI-17 phosphorylation. 
Interestingly, PKA is known to phosphorylate and activate PP2A in brain (30), so that CPI-17 
dephosphorylation could occur through cAMP/cGMP-activated PP2A. It should be noted that high activity of 
CPI-17 phosphatase(s) may explain why CPI-17 phosphorylation cannot be detected in thromboxane A2-
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stimulated cerebral artery from normal rat (31) or phenylephrine-stimulated mesentery arteries from genetically 
hypertensive rats (32). In addition to Thr38, purified PKC also phosphorylates Ser12 at the CPI-17 N-terminal 
tail, while CaMKII preferentially phosphorylates Ser130 at the CPI-17 C-terminal tail (9,33).  CPI-17 
phosphorylation at Ser128 was also detected in brain tissue extracts (33). However, the physiological relevance 
of this additional phosphorylation at both tails remains to be investigated.  The possibility that these sites are 
involved in regulating other target subsets, as reported for the phosphorylation of DARPP32 at Thr34 and Thr75 
that induces the inhibition of PP1 and PKA, respectively (34), cannot be discounted, however.   
 
  Expression of CPI-17:  CPI-17 is predominantly expressed in mature smooth muscle (10), and higher levels are 
present in tonic muscles, such as arteries (at 7 µM), compared with phasic muscles, such as ileum, bladder and 
vas deferens (at 0.8 µM), or cells in neointimal lesions (35,36).  CPI-17 is also expressed in embryonic cardiac 
muscle where smooth-muscle marker proteins are expressed, but its expression disappears in adult tissue (36). 
Platelet, neuron, endothelium and epithelium also express CPI-17, whose roles in these tissues will be discussed 
(35-37).  Accumulating evidence suggests a correlation between the CPI-17 expression level and the extent of 
PKC-mediated Ca2+ sensitized force. Selective permeabilization of smooth muscle tissue with Triton X-100 
eliminates the contraction induced by PKC activation, and the addition of recombinant CPI-17 restores PKC-
mediated contraction (38). The extent of smooth muscle contraction evoked by phorbol ester stimulation 
depends on the CPI-17 expression level (35). Interestingly, CPI-17 is absent in tissues from the American farm 
chicken, and as such provides an excellent model of CPI-17-null smooth muscle (39).  Stimulation with 
agonists, PDBu, or G-proteins evokes a marginal extent of the contraction of chicken aortic smooth muscle, 
suggesting the importance of CPI-17 in agonist-induced smooth muscle contraction (39).  Furthermore, 
fluctuations in CPI-17 signals reportedly occur under pathological conditions, such as hypertension, asthma, 
inflammation, and diabetes (40-45). For example, CPI-17 expression and phosphorylation are up-regulated in 
hypoxia-induced pulmonary hypertension (40).  CPI-17 up-regulation is also found in airway smooth muscle 
during inflammation and in diabetic bladder smooth muscle (41,45). In contrast, inflammation causes down-
regulation of CPI-17 in intestinal smooth muscle in parallel with a reduction in muscle tone (43).  How 
inflammatory signals trigger this bi-directional regulation of CPI-17 in different smooth muscle tissues remains 
unknown.  
 
  CPI-17 in other cell types:  Reversible phosphorylation of myosin is involved in controlling endothelial cell 
motility and platelet activation. CPI-17 in endothelial cells and platelets translates the activation of PKC and/or 
ROCK into MLCP inhibition and myosin-II phosphorylation as seen in smooth muscle (46,47).  In Purkinje 
neurons, CPI-17 is involved in long-term synaptic depression (37).  The synaptic depression of cerebellar 
Purkinje cells occurs through PKC-mediated chronic internalization of the AMPA receptor in response to 
glutamate release. Neutralization of endogenous CPI-17 in Purkinje cells using siRNA or a blocking antibody 
results in rapid recovery of membrane current upon glutamate stimulation (37), suggesting that metabotropic 
Glu receptor-induced activation of PKC causes CPI-17 phosphorylation and subsequent MLCP inhibition, thus 
maintaining  AMPA receptor internalization (37). Furthermore, CPI-17 drives cell proliferation by activating the 
MAP kinase signal pathway (48). Growth factor signals induce phosphorylation of merlin, a product of the 
neurofibromatosis type-2 gene, which relieves inhibition of the ERK1/2 signal. Merlin is phosphorylated by a 
subset of protein kinases, including ROCK, PAK and PKC, which are also capable of phosphorylating CPI-17.   
Overexpression of CPI-17 down- and up-regulates MLCP and merlin phosphorylation, respectively, and 
attenuates the tumor-suppression activity of merlin (48,49).  Over 90 % of cancer cells are derived from 
epithelial cells, where trace amounts of CPI-17 are expressed (35,36).  The role of CPI-17 in normal epithelium 
remains to be investigated. 
 
Functions of other CPI-17 family members 
 PHI: Both PHI-1 and -2 are products of the phospholipase C-neighboring gene (PNG, PPP1R14B) (50). PNG 
was originally discovered on chromosome 11 as a candidate gene involved in multiple endocrine neoplasia type 
1, although later studies eliminated that possibility. Two potential initiation ATG sequences exist in the PNG 
transcript (11,50).  Initiation at the first ATG yields a 203-residue polypeptide, named PHI-2, whereas the other 
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in-frame ATG initiates translation for the 147-residue PHI-1 (Fig. 1A, red triangle) (11).  PHI-1 is ubiquitously 
and abundantly expressed in various tissues and cultured cells.  In contrast, PHI-2 expression is restricted to 
muscle tissues (11). Immunohistochemical analysis showed a significant difference between CPI-17 and PHI-
1/2 localization, with the antibody recognizing both PHI-1 and PHI-2 heavily staining skeletal muscle capillary 
endothelium and the juxtamembrane region of the ileac smooth muscle layer (51).  Recombinant PHI-1 inhibits 
PP1 and the purified MLCP complex upon phosphorylation at Thr57 (11).  Phosphorylated PHI-1 evokes 
contraction of skinned smooth muscle strips (52).  However, the inhibitory potency of PHI-1 for the MLCP 
complex (IC50 = 50 nM) is significantly lower compared to CPI-17 (IC50 = 1 nM), suggesting novel target PP1 
holoenzymes for PHI-1. Purified PKC and ROCK are capable of phosphorylating PHI-1 at Thr57 and other 
undetermined site(s) (52), whereas ILK exclusively phosphorylates PHI-1 at Thr57 (52). Activation of G-
proteins in smooth muscle tissues induces the phosphorylation of endogenous PHI-1 (53,54).  On the other hand, 
reconstitution of unphosphorylated PHI-1 does not restore phorbol ester-induced contraction of CPI-17-null 
chicken smooth muscle (39).  Therefore, PHI-1 is not involved in PKC-mediated MLCP inhibition. The 
endothelial expression of PHI-1 is involved in cell migration (55).  Endogenous PHI-1 accumulates at the 
leading edge of endothelial cells, and gene silencing of PHI-1 can retard cell migration.  Interestingly, PHI-1 
knockdown does not affect the phosphorylation status of MLCP-substrate proteins, such as myosin light chain 
and ezrin/radixin/moesin (55), suggesting that PHI-1 controls a novel subset of PP1 holoenzymes in endothelial 
cells.   
 
  KEPI and GBPI:  KEPI (PPP1R14C, chromosome 6) was discovered as a protein that is up-regulated in brain 
tissue isolated from morphine-addicted mice (12). In terms of amino acid sequence KEPI seems to be more 
closely related to PHI-1 than CPI-17. The phosphorylation of KEPI at Thr75 by PKC is sufficient to convert this 
protein into a potent PP1 inhibitor (12).  A PP1-binding motif (-KVFF-) exists in the N-terminal tail of KEPI 
(Fig. 1A, green box).  Indeed, PP1 co-precipitates with beads conjugated with unphosphorylated KEPI (56).  
Purified PKC and ILK phosphorylates recombinant KEPI at Thr73, the inhibitory phosphorylation site (12,57).  
Phospho-KEPI inhibits the purified MLCP complex and isolated PP1 with an IC50 of 8 nM and 0.1 nM, 
respectively (57).  Therefore, phospho-KEPI potently inhibits the PP1 holoenzyme, but the N-terminal KVFF 
sequence of KEPI may affect its inhibitory potency.  Recently, KEPI was re-discovered in a group of genes that 
are down-regulated in breast tumor cells, along with a known tumor suppressor, phosphatase and tensin 
homolog (PTEN) (58). Ectopic expression of KEPI in MCF7 cells induces up-regulation of PTEN via 
augmentation of ERK1/2 phosphorylation.  Interestingly, although both CPI-17 and KEPI are involved in 
ERK1/2 phosphorylation, there is a clear contrast in their downstream signals (48,58), suggesting different pools 
of target PP1 holoenzymes may exist for each inhibitor. GBPI (PPP1R14D, chromosome 15) was discovered as 
a homologue of KEPI (13). The gene transcribes two splicing variants, GBPI and GBPI-2 (Fig. 1A).  GBPI 
includes an intact PHIN domain whose sequence is 35 % identical to CPI-17.  On the other hand, the testis-
specific GBPI-2 mRNA includes a frameshift at the A-B loop, and as such is unlikely to inhibit PP1. GBPI 
phosphorylated by PKC inhibits isolated PP1 with an IC50 value of 3 nM.  Phosphorylation of GBPI with PKA 
eliminates its inhibitory potency.  A PP1-binding motif, KVHW, is found in the N-terminal tail (Fig. 1A, green 
box), which is necessary for the inhibition of the isolated PP1 catalytic subunit (13). Whether GBPI is capable of 
inhibiting PP1 holoenzymes has yet to be tested.  Interestingly, GBPI enhances PP2A activity following its 
phosphorylation by PKC (13).  
 
Cellular regulation of PP1 holoenzymes via PP1 inhibitor proteins 
After the discovery of CPI-17 and CPI-17 family members, it becomes clear that PP1 inhibitor proteins 
characterized previously also engage in the control of cellular PP1 holoenzymes in the absence of subunit 
dissociation.  For example, PP1 inhibitor-2 (I-2) inhibits a complex of PP1 and a microtubule-binding kinase, 
Nek2 through the conserved C-terminal domain of I-2 (59),  which directly docks at the active site of PP1 in the 
co-crystal model of the PP1•I-2 complex (60).  In addition, PP1 inhibitor-1 and inhibitor-3 also inhibit PP1 
holoenzymes (reviewed in (3)).  Thus, each PP1 inhibitor protein may target a specific subset of PP1 
holoenzymes, and there are more PP1 inhibitor proteins that transduce kinase signals into phosphatases, as over 
100 polypeptides function as PP1 regulatory subunits. A proteomic approach (“PP1 inhibitome”) will be useful 
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to gain a full understanding of the specific combinations of kinases, PP1 holoenzymes and inhibitor proteins. As 
discussed here, CPI-17 as well as other PP1 inhibitor proteins plays vital roles in signal transduction controlling 
both amplitude and duration of phosphorylation. Additional PP1 inhibitor proteins will surely be re-discovered 
as disease-causing genes, and recognized as novel therapeutic targets. 
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1The abbreviations used are:  PP1, Ser/Thr protein phosphatase-1; MBS, myosin binding subunit; MLCP, 
myosin light chain phosphatase; MYPT1, myosin phosphatase-targeting subunit-1; CPI-17, C-kinase-activated 
PP1 inhibitor Mr=17 kDa; PHI, PP1 holoenzyme inhibitor; KEPI, Kinase C-enhanced PP1 inhibitor; GBPI, 
gastrointestinal- and brain-specific PP1 inhibitory protein, PKC, protein kinase C; ROCK, RhoA-activated 
coiled-coil kinase; ILK, integrin-linked kinase, PKA, protein kinase A; PKG, protein kinase G. 
2Supplemental figure for educational purposes. 
 
 
Figure Legend 
 
Fig. 1:  CPI-17 family.  (A) Schematic illustration of the CPI-17 family primary structure. The inhibitory 
phosphorylation site (red) is located in the conserved PP1 holoenzyme inhibitory (PHIN) domain (cyan box).  
Gray dots and green boxes indicate additional phosphorylation sites and PP1 binding motifs, respectively. (B) 
Electrostatic surface potential map of the CPI-17 family. The surface model of phospho-CPI-17 was used as a 
template, and putative models for other proteins were generated in-silico based on the sequence alignment.  The 
surface modeling was performed by Altif Laboratories (Tokyo, Japan).  
 
Fig. 2: A model for selective inhibition of MLCP by phospho-CPI-17. Upon phosphorylation of Thr38, CPI-17 
undergoes a conformational change that results in a re-alignment of the four helices A-D (middle).  Phospho-
CPI-17 docks at the active site of MLCP and suppresses its activity (right).  Other PP1 holoenzymes can 
dephosphorylate phospho-CPI-17 and neutralize its inhibitory potency.   
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